Epitomax to help migraine sufferers
The goal of migraine treatment is to provide relief and improve patients’ quality of life by reducing the frequency of attacks, their severity, duration, and incapacitation during/ between attacks. One such drug is Epitomax.
- Elimination of environmental and psychosocial factors contributing to the onset/ aggravation of headaches;
- Adequate therapy for the management of acute attacks;
- obligatory preventive treatment at high frequency of attacks, their considerable intensity, heavy manifestations of aura.
Despite the advances in the therapy of migraine, the disease remains difficult to treat. No more than ⅓ of patients receive appropriate preventive treatment. At the same time, some medications have been shown to be sufficiently effective in the management of migraine. One such drug is Epitomax. Studies have shown that a dose of 50-200 mg/day significantly reduces the frequency of migraine attacks in adults, and the effect may persist even after discontinuation.
According to the results of three randomized controlled multicenter trials it was established that in 46.3% of patients taking Epitomax the number of migraine attacks was reduced by 50%, in 6% of patients – attacks were completely terminated. According to the results of observation of migraine patients in the long-term period (6 months after Epitomax start), a progressive decrease of attacks frequency with increasing duration of Epitomax use was detected.
The efficacy of Epitomax (50 mg/day), propranololol (80 mg/day) and valproic acid (400 mg/day) on headache frequency, intensity and duration is generally comparable.
The most common side effects of Epitomax therapy – paresthesias, weakness, lack of appetite, nausea – usually occur when used in high doses, usually appear in the first 2 months of treatment and in most cases pass on their own.
Against the background of Epitomax administration, sweating reduction and hyperthermia are possible, especially in young children in conditions of high ambient temperature. Sufficient fluid replacement before and during activities such as exercise or exposure to high temperatures can reduce the risk of overheating-related complications.
Patients should be monitored during the treatment period for signs of suicidal ideation and appropriate treatment should be prescribed. Patients (and their caregivers, if necessary) should be advised to seek immediate medical attention if signs of suicidal ideation or suicidal behavior appear.
If visual disturbances occur, including syndrome involving myopia associated with closed-angle glaucoma, Epitomax should be discontinued as soon as the treating physician considers it possible. If necessary, measures should be taken to lower intraocular pressure.